Abstract | BACKGROUND: OBJECTIVES: METHODS: Using a thrombotic middle cerebral artery occlusion (MCA-O) model, ICB was studied in mice with genetic deficiencies of plasminogen (Plg(-/-)), stromelysin-1 ( MMP-3(-/-)), or gelatinase B ( MMP-9(-/-)) and their corresponding wild-type (WT) littermates. The induction of MMP-3 and MMP-9 was also studied in C57BL/6 WT mice. RESULTS: ICB induced by t- PA (10 mg kg(-1)) was significantly less than WT in Plg(-/-) (P < 0.05) and MMP-3(-/-) (P < 0.05) but not in MMP-9(-/-) mice. Furthermore, administration of the broad-spectrum MMP inhibitor GM6001 after t-PA treatment reduced ICB significantly (P < 0.05) in MMP-3(+/+) mice, but had no effect on MMP-3(-/-) mice. MMP-3 expression was significantly enhanced at the ischemic hemisphere; with placebo treatment, it was expressed only in neurons, whereas it was up-regulated in endothelial cells with t-PA treatment. Although MMP-9 expression was also significantly enhanced at the ischemic brain, the amount and the distribution were comparable in mice with and without t-PA treatment. CONCLUSIONS: Our data with gene-deficient mice thus suggest that plasminogen and MMP-3 are relatively more important than MMP-9 for the increased ICB induced by t-PA treatment of ischemic stroke.
|
Authors | Y Suzuki, N Nagai, K Umemura, D Collen, H R Lijnen |
Journal | Journal of thrombosis and haemostasis : JTH
(J Thromb Haemost)
Vol. 5
Issue 8
Pg. 1732-9
(Aug 2007)
ISSN: 1538-7933 [Print] England |
PMID | 17596135
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Placebos
- Tissue Plasminogen Activator
- Matrix Metalloproteinase 3
- Mmp3 protein, mouse
- Matrix Metalloproteinase 9
- Mmp9 protein, mouse
|
Topics |
- Animals
- Gene Expression Regulation
- Intracranial Hemorrhages
(enzymology, etiology)
- Ischemia
(complications)
- Matrix Metalloproteinase 3
(physiology)
- Matrix Metalloproteinase 9
(metabolism)
- Mice
- Mice, Inbred C57BL
- Mice, Transgenic
- Models, Genetic
- Neurons
(metabolism)
- Placebos
- Stroke
(blood, complications, drug therapy)
- Thrombolytic Therapy
(methods)
- Tissue Plasminogen Activator
(therapeutic use)
|